A Phase I Study of LY3502970 in Healthy Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT06085482
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
21 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • LY3502970 — DRUG
    Administered orally
  • [14C]-LY3502970 — DRUG
    Administered IV

Study Details

The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.

Key Dates

Start date
Oct 19, 2023
Status verified
Apr 2026
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3502970 + [14C]-LY3502970
    Participants received a single oral dose of 1 milligram (mg) LY3502970 followed six hours later by an intravenous (IV) dose of approximately 21 microgram (μg) of LY3502970 radiolabeled with carbon-14 (\[14C\]-LY3502970) containing approximately 800 nanocurie (nCi) radioactivity.

Primary Outcome Measure

Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 [ Time Frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Covance Clinical Research IncMadisonWisconsin53704-

Related coverage on Hipa.ai

Find similar trials in Madison, WI

By research site
Covance Clinical Research Inc· Madison, WI

Related Studies